Sneed Jr. v. AcelRx Pharmaceuticals, Inc. ( 2023 )

1 2 3 UNITED STATES DISTRICT COURT 4 NORTHERN DISTRICT OF CALIFORNIA 5 SAN JOSE DIVISION 6 7 AARON SNEED JR., Case No. 21-cv-04353-BLF 8 Plaintiff, ORDER GRANTING MOTION TO 9 v. DISMISS SECOND AMENDED COMPLAINT WITH LEAVE TO 10 ACELRX PHARMACEUTICALS, INC., et AMEND IN PART AND WITHOUT al., LEAVE TO AMEND IN PART 11 Defendants. [Re: ECF No. 78] 12 13 Now before the Court is Defendants’ motion to dismiss the Second Amended Complaint in 14 this putative securities class action. ECF No. 78 (“MTD”); see also ECF No. 83 (“Reply”). 15 Plaintiffs oppose the motion. ECF No. 82 (“Opp.”). For the reasons discussed at the May 30, 16 2023 motion hearing and further explained below, the Court GRANTS Defendants’ motion to 17 dismiss WITH LEAVE TO AMEND IN PART and WITHOUT LEAVE TO AMEND IN PART. 18 I. BACKGROUND 19 On June 8, 2021, Plaintiff Aaron Sneed Jr. filed a securities class action suit in this Court 20 alleging violations of various securities laws by AcelRx Pharmaceuticals, Inc. (“AcelRx”), AcelRx 21 Chief Executive Officer Vincent J. Angotti, and AcelRx Chief Financial Officer Raffi Asadorian. 22 ECF No. 1. The Court appointed Aaron Sneed Jr. and Yaacov Musry as co-lead plaintiffs and 23 Pomerantz LLP as lead counsel. ECF No. 47. On March 3, 2022, Plaintiffs filed an amended 24 complaint. ECF No. 54. The amended complaint added one additional Defendant, AcelRx Chief 25 Health Officer Pamela Palmer. Id. On September 28, 2022, the Court dismissed the amended 26 complaint with leave to amend. Sneed v. AcelRx Pharms., Inc., No. 21-cv-04353-BLF, 2022 WL 27 4544721 (N.D. Cal. Sept. 28, 2022). 1 75 (“SAC”). Plaintiffs bring suit against AcelRx, Angotti, Asadorian, and Palmer, asserting three 2 counts under the Securities and Exchange Act of 1934 (“Exchange Act”) on behalf of a class 3 including all individuals who purchased or otherwise acquired AcelRx securities (ticker symbol 4 ACRX) between March 20, 2019 and February 12, 2021. Id. 5 AcelRx is a pharmaceutical company that develops therapies for the treatment of acute 6 pain. SAC ¶ 37. DSUVIA, the product at the center of this suit, is an opioid painkiller that is 7 administered sublingually and therefore particularly useful in circumstances where patients cannot 8 swallow oral medication and access to intravenous pain relief is not possible. Id. ¶¶ 37-38. In 9 November 2018, the U.S. Food and Drug Administration (“FDA”) approved AcelRx’s application 10 for DSUVIA. Id. ¶ 63. In so doing, the FDA also approved the DSUVIA Risk Evaluation and 11 Mitigation Strategy (“REMS”), which is “a drug safety program that the [FDA] can require for 12 certain medications with serious safety concerns to help ensure the benefits of the medication 13 outweigh its risks.” Id. ¶¶ 40, 63. As an FDA-approved drug, DSUVIA is subject to the Federal 14 Food, Drug, and Cosmetic Act (“FDCA”), which prohibits the introduction into interstate 15 commerce of any drug that is “misbranded.” Id. ¶ 8, 114; see 21 U.S.C. § 331. 16 On February 11, 2021, AcelRx received a warning letter from the FDA’s Office of 17 Prescription Drug Promotion (“OPDP”). SAC ¶ 18. The letter (“Warning Letter”) indicated that 18 two of AcelRx’s promotional materials—a banner advertisement and a tabletop display—made 19 “false or misleading claims and representations about the risks and efficacy of DSUVIA” and 20 therefore violated the FDCA (the “Misbranding Violations”). Id. ¶¶ 18-19. The Warning Letter 21 stated that the Misbranding Violations were “particularly concerning considering a REMS 22 program was required for DSUVIA to ensure that the benefits of the drug outweigh the risk of 23 respiratory depression that can result from accidental exposure.” Id. ¶ 176. After AcelRx publicly 24 disclosed this letter on February 16, 2021, the stock price fell $0.21 per share, or 8.37%. Id. ¶ 23. 25 Also on February 16, 2021, the FDA issued a press release entitled, “FDA issues warning to 26 AcelRx for making false and misleading claims about the risks and benefits of DSUVIA.” Id. ¶ 27 182. The press release stated that the tabletop display and banner advertisement “undermine key 1 undercut[] FDA-required conditions on the proper administration of the drug, which requires 2 particular diligence to minimize the risk of serious or even fatal adverse events.” Id. ¶ 184. It 3 went on to explain that DSUVIA “was approved with a [REMS].” Id. 4 Plaintiffs allege that “Defendants made false and/or misleading statements and/or failed to 5 disclose that: (1) AcelRx failed to implement and/or maintain sufficient disclosure controls and 6 procedures regarding the marketing of DSUVIA; (2) as a result, the Company engaged in the 7 Misbranding Violations; and (3) the Company was therefore subject to a foreseeable and increased 8 risk of regulatory investigations or enforcement actions. As a result, the Company’s public 9 statements were materially false and misleading throughout the Class Period.” SAC ¶ 15. 10 Plaintiffs also allege that Defendants “engaged in a scheme to illegally market DSUVIA beyond 11 its permitted label.” Id. ¶ 14. 12 Plaintiffs assert three claims: (1) violation of Section 10(b) of the Exchange Act and Rule 13 10b-5(b) by all Defendants, SAC ¶¶ 199-206; (2) violation of Section 10(b) of the Exchange Act 14 and Rule 10b-5(a), (c) by all Defendants, id. ¶¶ 207-16; and (3) violation of Section 20(a) of the 15 Exchange Act by Defendants Angotti, Asadorian, and Palmer, id. ¶¶ 217-23. 16 II. LEGAL STANDARD 17 “A motion to dismiss under Federal Rule of Civil Procedure 12(b)(6) for failure to state a 18 claim upon which relief can be granted ‘tests the legal sufficiency of a claim.’” Conservation 19 Force v. Salazar, 646 F.3d 1240, 1241–42 (9th Cir. 2011) (quoting Navarro v. Block, 250 F.3d 20 729, 732 (9th Cir. 2001)). When determining whether a claim has been stated, the Court accepts 21 as true all well-pled factual allegations and construes them in the light most favorable to the 22 plaintiff. Reese v. BP Expl. (Alaska) Inc., 643 F.3d 681, 690 (9th Cir. 2011). But the Court need 23 not “accept as true allegations that contradict matters properly subject to judicial notice” or 24 “allegations that are merely conclusory, unwarranted deductions of fact, or unreasonable 25 inferences.” In re Gilead Scis. Sec. Litig., 536 F.3d 1049, 1055 (9th Cir. 2008) (internal quotation 26 marks and citations omitted). While a complaint need not contain detailed factual allegations, it 27 “must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible 1 550 U.S. 544, 570 (2007)). A claim is facially plausible when it “allows the court to draw the 2 reasonable inference that the defendant is liable for the misconduct alleged.” Id. 3 In addition to the pleading standards discussed above, a plaintiff asserting a private 4 securities fraud action must meet the heightened pleading requirements imposed by Federal Rule 5 of Civil Procedure 9(b) and the Private Securities Litigation Reform Act of 1995 (“PSLRA”). In 6 re VeriFone Holdings, Inc. Sec. Litig., 704 F.3d 694, 701 (9th Cir. 2012). Rule 9(b) requires a 7 plaintiff to “state with particularity the circumstances constituting fraud . . . .” Fed. R. Civ. P. 8 9(b); see also In re VeriFone Holdings, 704 F.3d at 701. Similarly, the PSLRA requires that “the 9 complaint shall specify each statement alleged to have been misleading, [and] the reason or 10 reasons why the statement is misleading . . . .” 15 U.S.C. § 78u-4(b)(1)(B). The PSLRA further 11 requires that the complaint “state with particularity facts giving rise to a strong inference that the 12 defendant acted with the required state of mind.” Id. § 78u-4(b)(2)(A). “To satisfy the requisite 13 state of mind element, a complaint must allege that the defendant[] made false or misleading 14 statements either intentionally or with deliberate recklessness.” In re VeriFone Holdings, 704 15 F.3d at 701 (internal quotation marks and citation omitted) (alteration in original). The scienter 16 allegations must give rise not only to a plausible inference of scienter, but to an inference of 17 scienter that is “cogent and at least as compelling as any opposing inference of nonfraudulent 18 intent.” Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308, 314 (2007). 19 III. REQUEST FOR JUDICIAL NOTICE 20 Ordinarily, a district court's inquiry on a Rule 12(b)(6) motion to dismiss is limited to the 21 pleadings. “A court may, however, consider certain materials—documents attached to the 22 complaint, documents incorporated by reference in the complaint, or matters of judicial notice— 23 without converting the motion to dismiss into a motion for summary judgment.” United States v. 24 Ritchie, 342 F.3d 903, 908 (9th Cir. 2003). Courts may take judicial notice of facts that are “not 25 subject to reasonable dispute.” Fed. R. Evid. 201(b). Indisputable facts are those that are 26 “generally known” or that “can be accurately and readily determined from sources whose accuracy 27 cannot reasonably be questioned.” Id. 1 issued on November 2, 2018; Exhibit 2, DSUVIA REMS, approved by FDA on November 2, 2 2018; Exhibit 3, DSUVIA Prescribing Information, approved by FDA on November 2, 2018; 3 Exhibit 4, DSUVIA Directions for Use; Exhibit 5, AcelRx Press Release, issued on January 7, 4 2019; Exhibit 6, AcelRx Press Release, issued on January 31, 2019; Exhibit 7, Excerpts of AcelRx 5 Form 10-K (FY 2018), filed with SEC on March 7, 2019; Exhibit 8, Transcript of AcelRx 6 presentation at the 29th Annual Oppenheimer Health Care Conference, webcast live on March 20, 7 2019; Exhibit 9, AcelRx Press Release, issued on April 11, 2019; Exhibit 10, Excerpts of AcelRx 8 Form 10-Q (Q1 2019), filed with SEC on May 9, 2019; Exhibit 11, Transcript of AcelRx Q2 2019 9 earnings call, held on August 5, 2019; Exhibit 12, Excerpts of AcelRx Form 10-Q (Q2 2019), filed 10 with SEC on August 6, 2019; Exhibit 13, Transcript of AcelRx Q3 2019 earnings call, held on 11 November 6, 2019; Exhibit 14, Excerpts of AcelRx Form 10-Q (Q3 2019), filed with SEC on 12 November 7, 2019; Exhibit 15, Transcript of AcelRx Q4 2019 earnings call, held on March 16, 13 2020; Exhibit 16, Excerpts of AcelRx Form 10-K (FY 2019), filed with SEC on March 16, 2020; 14 Exhibit 17, Transcript of AcelRx Q1 2020 earnings call, held on May 11, 2020; Exhibit 18, 15 Excerpts of AcelRx Form 10-Q (Q1 2020), filed with SEC on May 11, 2020; Exhibit 19, Excerpts 16 of AcelRx Form 10-Q (Q2 2020), filed with SEC on August 10, 2020; Exhibit 20, Excerpts of 17 AcelRx Form 10-Q (Q3 2020), filed with SEC on November 5, 2020; Exhibit 21, AcelRx Form 8- 18 K, filed with SEC on February 16, 2021; Exhibit 22, Analyst report published on February 16, 19 2021; Exhibit 23, Analyst report published on February 17, 2021; Exhibit 24, AcelRx Press 20 Release, issued on May 16, 2022; Exhibit 25, FDA Memorandum issued on November 1, 2018; 21 Exhibit 26, AcelRx Press Release, issued on May 19, 2022; and Exhibit 27, FDA webpage on 22 Prescription Drug Advertising: Questions and Answers. ECF No. 79 (“RJN”); see Declaration of 23 Janelle M. Fernandes, ECF No. 80 (“Fernandes Decl.”), Exs. 1-27. Plaintiffs take no position on 24 the request. 25 The incorporation by reference doctrine permits the Court to take into account documents 26 “whose contents are alleged in a complaint and whose authenticity no party questions, but which 27 are not physically attached to the [plaintiff's] pleading.” Knievel v. ESPN, 393 F.3d 1068, 1076 1 finds that Exhibits 1-3, 8, 10, 12, 14-16, 18-22, and 25 are incorporated by reference into the SAC. 2 See, e.g., SAC ¶¶ 4, 63 (Ex. 1); ¶¶ 5, 20, 63 (Ex. 2); ¶ 119 (Ex. 3); ¶ 127 (Ex. 8); ¶¶ 131, 133 (Ex. 3 10); ¶¶ 135, 137 (Ex. 12); ¶¶ 139, 141 (Ex. 14); ¶¶ 150, 152 (Ex. 15); ¶¶ 143-44, 146, 148 (Ex. 4 16); ¶¶ 154, 156 (Ex. 18); ¶¶ 158, 160 (Ex. 19); ¶¶ 162, 164, 166, 168 (Ex. 20); ¶¶ 18, 171-73 (Ex. 5 21); ¶ 186 (Ex. 22); ¶ 47 (Ex. 25). 6 The remaining documents include an SEC filing, AcelRx Form 10-K (FY 2018) (Ex. 7); 7 pages from the AcelRx and FDA websites (Exs. 4, 27); press releases (Exs. 5-6, 9, 24, 26); 8 transcripts of earnings calls (Exs. 11, 13, 17); and an analyst report (Ex. 23), all of which are 9 proper subjects of judicial notice. See Metzler Inv. GMBH v. Corinthian Colleges, Inc., 540 F.3d 10 1049, 1064 n.7 (SEC filings); Calhoun v. Google LLC, 526 F. Supp. 3d 605, 617 (N.D. Cal. 2021) 11 (publicly available websites); In re Am. Apparel, Inc. S’holder Litig., 855 F. Supp. 2d 1043, 1062 12 (C.D. Cal. 2012) (press releases); In re Extreme Networks, Inc. Sec. Litig., No. 15-cv-04883-BLF, 13 2018 WL 1411129, at *10 (N.D. Cal. Mar. 21, 2018) (conference call transcripts); City of 14 Dearborn Heights Act 345 Police & Fire Ret. Sys. v. Align Tech., Inc., No. 12-cv-06039-WHO, 15 2013 WL 6441843, at *5 (N.D. Cal. Dec. 9, 2013) (analyst reports). These exhibits are all 16 publicly available, and their accuracy is not disputed by Plaintiffs. The Court thus takes judicial 17 notice of the existence of these exhibits. The Court does not take notice of the truth of any of the 18 facts asserted in these documents. See City of Sunrise Firefighters’ Pension Fund v. Oracle Corp., 19 No. 18-cv-04844-BLF, 2019 WL 6877195, at *23 (N.D. Cal. Dec. 17, 2019). 20 Defendants’ request for judicial notice is GRANTED. 21 IV. DISCUSSION 22 Defendants move to dismiss the complaint for failure to meet the pleading requirements for 23 all claims. See MTD. 24 A. Claim 1: Section 10(b) and Rule 10b-5(b) 25 Plaintiffs bring a claim under Section 10(b) of the Exchange Act and the associated Rule 26 10b-5(b). SAC ¶¶ 199-206. Section 10(b) makes it unlawful “for any person . . . [t]o use or 27 employ, in connection with the purchase or sale of any security . . . any manipulative or deceptive 1 prescribe[.]” 15 U.S.C. § 78j(b). Rule 10b-5, promulgated by the Securities and Exchange 2 Commission under the authority of § 10(b), in turn makes it unlawful for any person, 3 (a) To employ any device, scheme or artifice to defraud, 4 (b) To make any untrue statement of a material fact or to omit to state a material 5 fact necessary in order to make the statements made, in light of the circumstances under which they were made, not misleading, or 6 (c) To engage in any act, practice, or course of business which operates or would 7 operate as a fraud or deceit upon any person, 8 in connection with the purchase or sale of any security. 17 C.F.R. § 240.10b-5. To state a securities fraud claim, a plaintiff must plead: “(1) a material 9 misrepresentation or omission; (2) scienter; (3) a connection between the misrepresentation or 10 omission and the purchase or sale of a security; (4) reliance; (5) economic loss; and (6) loss 11 causation.” Dearborn Heights, 856 F.3d at 613. Defendants’ motion is predicated on 12 requirements one and two. See MTD at 8-22. 13 14 1. Falsity Defendants argue that the SAC should be dismissed because Plaintiffs have not adequately 15 alleged any false statements. MTD at 8-17. 16 To plead falsity, a plaintiff must plead “specific facts indicating why” the statements at 17 issue were false. Metzler, 540 F.3d at 1070. “[T]o meet the requirements of Rule 9(b), Plaintiffs 18 must, for each allegedly false or misleading statement, clearly allege with particularity why the 19 statement was false or misleading at the time it was made.” Norfolk Cnty. Ret. Sys. v. Solazyme, 20 Inc., No. 15-cv-02938-HSG, 2016 WL 7475555, at *3 (N.D. Cal. Dec. 29, 2016); see also In re 21 Stac Elecs. Sec. Litig., 89 F.3d 1399, 1404 (9th Cir. 1996) (“[S]tatement or omission must be 22 shown to have been false or misleading when made.”). 23 Plaintiffs point to 23 statements that they allege were false or misleading. See ECF No. 76 24 (“SAC App. 1”). Defendants argue that none are false. MTD at 8-17. The Court will address 25 each category of statement in turn. 26 Statements About DSUVIA’s Use and Administration 27 1 1; SAC ¶¶ 118, 127, 129. Statement 2 is the tabletop display, and Statement 3 is the banner 2 advertisement. SAC App. 1; SAC ¶¶ 118, 129. These two advertisements were the subject of the 3 FDA warning letter, and both include the “Tongue and Done” slogan that the FDA ultimately 4 determined was “misleading because [it] impl[ies] that the administration of DSUVIA consists of 5 a simple, one-step process, when this is not the case.” See SAC App. 1; SAC ¶¶ 118, 175. And 6 Statement 1 is a statement made by Defendant Angotti at the AcelRx presentation at the 7 Oppenheim Health Care Conference about how to administer DSUVIA: “You would simply 8 remove the lock, tell the patient in the ER and post-op or the soldier [to] tilt their head back, lift up 9 their tongue, you inject it under and you’re done. And it’s basically as simple as that.” SAC App. 10 1; SAC ¶¶ 127. Plaintiffs allege that these statements about the administration of DSUVIA were 11 misleading because they omitted material information, including information about dosing, 12 administration, and limitations of use. See SAC App. 1; SAC ¶¶ 118, 127, 129. They also allege 13 falsity on the basis that AcelRx failed to implement or maintain sufficient controls and procedures 14 regarding the marketing of DSUVIA, and therefore the company was subject to a foreseeable and 15 increased risk of regulatory investigations or enforcement actions. See SAC App. 1; SAC ¶¶ 128, 16 130. 17 Defendants argue that these statements were not false or misleading for several reasons. 18 First, they argue that Plaintiffs have not alleged that the statements were false when made, as 19 Plaintiffs allegations of falsity are based on the Warning Letter, which was issued after the 20 statements were made. MTD at 9-10. Defendants next assert that the allegedly omitted “material 21 information” was disclosed to investors, as Defendants disclosed safety information and 22 limitations of use, and that “no reasonable investor would have viewed these statements as 23 providing comprehensive instructions for use.” Id. at 12-13. Defendants then assert that Plaintiffs 24 did not plead how Defendants’ failures regarding internal controls resulted in an increased risk of 25 regulatory investigations or enforcement actions. Id. at 13. And Defendants argue that these 26 statements are not actionable because Plaintiffs do not plead that any of the three Individual 27 Defendants was a “maker” of any of the statements. Id. at 13-14. 1 misleading. Defendants argue that the statements could not have been false when made because 2 the Warning Letter did not come out until months after the statements were made. MTD at 9-10. 3 In Norfolk County Retirement System v. Solazyme, Inc., the court dismissed the plaintiffs’ Section 4 10 claim. See 2016 WL 7475555. It explained that “[t]hroughout the complaint, Plaintiffs 5 reference facts they claim establish that key representations were false or misleading when made, 6 but they consistently fail to allege that the facts existed and were known to Defendants at the time 7 the statements were made.” Id. at *3. The Court thinks that the current situation is 8 distinguishable. Here, facts about DSUVIA’s proper use, limitations, and administration were 9 known at the time that the statements were made, as can be gleaned from Plaintiffs’ allegations 10 about the extensive and iterative FDA process that AcelRx went through to obtain approval for 11 DSUVIA. See SAC ¶¶ 39-63. The timing of the Warning Letter in relation to the statements is 12 more indicative of scienter, which the Court will address below. 13 Plaintiffs’ theory about an increased risk of regulatory scrutiny is less convincing. See 14 SAC ¶¶ 128, 130. As to Defendant Angotti’s statement, Plaintiffs allege that Angotti “undermined 15 the REMS” and, “as a result, the Company was therefore subject to a foreseeable and increased 16 risk of regulatory investigations or enforcement actions.” Id. ¶ 128. As to the banner 17 advertisement and tabletop display, Plaintiffs allege that “AcelRx failed to implement and/or 18 maintain sufficient internal controls and procedures regarding the marketing of DSUVIA” and, “as 19 a result, the Company was therefore subject to a foreseeable and increased risk of regulatory 20 investigations or enforcement actions.” Id. ¶ 130. This is an instance where “the reasons . . . why 21 . . . the statements are false or misleading bear no connection to the substance of the statements.” 22 See Veal v. LendingClub Corp., 423 F. Supp. 3d 785, 807 (N.D. Cal. 2019). 23 Defendants argue that the allegedly omitted material information was actually disclosed to 24 investors and that no reasonable investor would have viewed the statements as providing 25 comprehensive instructions for use. MTD at 12-13. Plaintiffs counter that this “truth on the 26 market” defense by Defendants lacks merit. Opp. at 16-18. The Court recognizes that full 27 information about the use and administration of DSUVIA was publicly available. Such a 1 2012 WL 4477647, at *8 (N.D. Cal. Sept. 27, 2012) (considering statements “in the context” of 2 information that was “well-known and understood by the FDA . . . and by the markets”). But the 3 Court declines to find that the statements were not false or misleading on this basis at the motion 4 to dismiss stage. See In re Turnstone Sys. Sec. Litig., No. C 01-1256 SBA, 2003 U.S. Dist. LEXIS 5 26709, at *127-28 (N.D. Cal. Feb. 4, 2003) (recognizing the truth-on-the-market defense is 6 “generally inappropriate” at the motion to dismiss stage “because it raises distinctly factual 7 issues”). 8 Finally, Defendants also argue that the Individual Defendants were not “makers” of these 9 statements. MTD at 13-14. “For purposes of Rule 10b–5, the maker of a statement is the person 10 or entity with ultimate authority over the statement, including its content and whether and how to 11 communicate it.” Janus Cap. Grp., Inc. v. First Derivative Traders, 564 U.S. 135, 142 (2011). 12 The Court notes that Defendant Angotti was clearly the “maker” of Statement 1, but there are no 13 allegations that the other two Individual Defendants were “makers” of this Statement. See SAC ¶ 14 127. As to the other two statements, in arguing that the Individual Defendants were “makers” of 15 the statements, Plaintiffs point the Court to two paragraphs of the SAC, both of which allege that 16 the Individual Defendants had the “power and authority” or “control and authority” to control the 17 contents of the statements. See Opp. at 13 (citing SAC ¶¶ 35, 203). While these allegations are 18 fairly conclusory, Plaintiffs do provide some additional allegations that Defendants Angotti and 19 Palmer had some degree of control over Statements 2 and 3. See SAC ¶¶ 102 (alleging Angotti 20 “weighed in on” marketing materials), 110 (alleging Angotti and Palmer were present at a meeting 21 in which the “Tongue and Done” slogan was discussed and provided input as to use of the slogan). 22 The Court determines that the allegations are sufficient for purposes of the motion to dismiss. See 23 In re Rocket Fuel, Inc. Sec. Litig., No. 14-cv-3998-PJH, 2015 WL 9311921, at *10 (N.D. Cal. 24 Dec. 23, 2015) (determining the plaintiffs had alleged the defendants were “makers” of the 25 statements for purposes of the motion to dismiss where the “complaint does indeed allege that the 26 three Insider defendants ‘possessed the power and authority to control the contents of the 27 Company's press releases [and] investor and media presentations’” (citation omitted)). 1 Risk Factors 2 Statements 4, 6, 8, 22, and 23 are all related to risk factors. See SAC App. 1; SAC ¶¶ 131, 3 135, 139, 166, 168. Statements 4, 6, and 8 provide that “[t]he success of DSUVIA will depend on 4 numerous factors, including . . . effective management of and compliance with the DSUVIA Risk 5 Evaluation and Mitigation Strategies, or REMS program [and] continued demonstration of an 6 acceptable safety profile of DSUVIA following approval.” SAC App. 1; SAC ¶¶ 131, 135, 139. 7 Statement 22 identifies several risks, including that (1) guidelines and recommendations from 8 government agencies and non-governmental organizations, as well as existing laws and 9 regulations, can reduce the use of DSUVIA; (2) AcelRx may be unable to generate sufficient 10 revenue if unable to maintain or grow its sales and marketing capabilities or enter into agreements 11 with third parties to market and sell products; and (3) a key part of the business strategy is to 12 establish relationships to commercialize and fund development and approval of the products, and 13 AcelRx may not succeed in doing so. SAC App. 1; SAC ¶¶ 166. Statement 23 reiterates the 14 portion of Statement 22 about generating sufficient revenue, and it also provides that AcelRx must 15 maintain or grow internal sales, marketing, distribution, managerial and other capabilities or make 16 arrangements with third parties to do so in order to commercialize DSUVIA. SAC App. 1; SAC 17 ¶¶ 168. Defendants argue that Plaintiffs have not alleged falsity as to these statements about risk 18 factors. MTD at 14-15. Plaintiffs argue that Statements 4, 6, and 8 were false because AcelRx 19 was engaging in the Misbranding Violations, which they assert undermined the REMS. Opp. at 20 15; see also SAC App. 1; SAC ¶¶ 171-84. 21 “The Ninth Circuit has noted that ‘risk factors’ are not actionable without further factual 22 allegations indicating that the risks had already ‘come to fruition.’” In re Pivotal Sec. Litig., No. 23 No. 3:19-cv-03589-CRB, 2020 WL 4193384, at *6 (N.D. Cal. July 21, 2020) (quoting Siracusano 24 v. Matrixx Initiatives, Inc., 585 F.3d 1167, 1181 (9th Cir. 2009)); see also Flynn v. Sientra, Inc., 25 No. CV 15-07548 SJO (RAOx), 2016 WL 3360676, at *11 (C.D. Cal. June 9, 2016) (holding that 26 statements about risks were “ more than plausibly misleading when viewed in conjunction with 27 Plaintiffs' allegations that serious regulatory issues had already transpired by the time these 1 issues”). As Defendants argue, Plaintiffs here had not alleged that any of the risks being warned 2 of had already come to fruition at the time the statements were made. See MTD at 14-15. For 3 example, as to Statements 4, 6, and 8, Plaintiffs have not alleged that AcelRx had not effectively 4 managed or complied with the REMS nor that DSUVIA no longer demonstrated an acceptable 5 safety profile. See SAC. The same is true of the risks identified in Statements 22 and 23. 6 Plaintiffs have not alleged falsity as to the risk statements. 7 Earnings Call Statement 8 Statement 15 was made by Defendant Palmer during a quarterly earnings call on March 16, 9 2020: 10 AcelRx ensures proper use of DSUVIA via physician education and the DSUVIA risk evaluation and mitigation strategies or REMS 11 program. DSUVIA is only available to facilities that are part of the DSUVIA REMS program. Facilities that administer DSUVIA must 12 be able to . . . ensure the appropriate administration of DSUVIA. All safety information and the black box warning for DSUVIA can be 13 found at dsuvia.com. 14 SAC App. 1; SAC ¶ 152. 15 Defendants argue that Plaintiffs have not alleged the falsity of this statement. MTD at 10- 16 11. Plaintiffs do not argue otherwise. See Opp. The Court agrees that Plaintiffs have not alleged 17 the falsity of the statement, as Plaintiffs have not alleged that AcelRx was not complying with the 18 REMS. See SAC. 19 Sales and Marketing Efforts 20 Statement 10 addresses AcelRx’s sales and marketing practices for DSUVIA. See SAC 21 App. 1; SAC ¶ 143. It provides that Defendants were using a scientific support team to understand 22 hospital needs to present DSUVIA effectively; had increased awareness of sublingual 23 administration of sufentanil by publishing data; had engaged Advisory Boards that included 24 various medical professionals and other experts to provide input on commercial positioning for 25 DSUVIA; had developed a sales and marketing organization; and had deployed a team to explain 26 the benefits of DSUVIA at medical centers. Id. As Defendants point out, the SAC does not allege 27 that these activities did not occur. See Opp. at 14. Plaintiffs have not alleged falsity as to this 1 SOX Certifications and Controls 2 Statements 5, 7, 9, 13, 17, 19, and 21 are all SOX certifications. See SAC App. 1; SAC ¶¶ 3 133, 137, 141, 148, 156, 160, 164. These SOX certifications “are wholly untethered to Plaintiffs' 4 described reasons for falsity.” See Veal, 423 F. Supp. 3d at 808. These statements provide that 5 certain SEC filings complied with the Exchange Act and “fairly present[], in all material respects, 6 the financial condition and results of operations of the Company.” See SAC App. 1. The SAC 7 does not include allegations about the financial condition or results of operations at AcelRx. 8 “Absent any allegations of financial wrongdoing, the SOX certifications have no nexus to 9 Plaintiffs’ reasons for falsity.” Veal, 423 F. Supp. 3d at 808; see In re Banco Bradesco S.A. Sec. 10 Litig., 277 F. Supp. 3d 600, 654 (S.D.N.Y. 2017) (“Plaintiff has failed to plead that [the SOX] 11 certification was false or misleading because . . . the amended complaint does not adequately 12 allege a nexus between the alleged [wrongful act] and [the company's] financial condition or 13 results of operations, or that the Company's financial reports contained inaccuracies.” (emphasis 14 in original)). Plaintiffs have not alleged falsity as to the SOX certifications. 15 Statements 12, 16, 18, and 20 are all SOX controls and procedure verification statements. 16 See SAC App. 1; SAC ¶¶ 146, 154, 158, 162. These statements provided that AcelRx’s 17 “disclosure controls and procedures were effective.” See SAC App. 1. Again, these SOX 18 statements “are wholly untethered to Plaintiffs' described reasons for falsity.” See Veal, 423 F. 19 Supp. 3d at 808. The term “disclosure controls and procedures” means “controls and other 20 procedures of an issuer that are designed to ensure that information required to be disclosed by 21 the issuer in the reports that it files or submits under the Act (15 U.S.C. 78a et seq.) is recorded, 22 processed, summarized and reported, within the time periods specified in the Commission's rules 23 and forms.” 17 C.F.R. § 240.13a-15(e). Plaintiffs make no allegations that Defendants’ 24 disclosure controls and procedures were not actually effective. See SAC. Plaintiffs have not 25 alleged falsity as to these statements. 26 Forward-Looking Statements 27 Statement 11 provides that AcelRx “may adjust [its] commercialization plan” by, among 1 experienced sales organization in the United States dedicated to bringing innovative, highly valued 2 healthcare solutions to patients, payers and healthcare providers,” as needed, and by “continuing to 3 establish DSUVIA as a suitable choice for moderate-to-severe acute pain in certified medically 4 supervised settings.” See SAC App. 1; SAC ¶ 144. Defendants argue that this statement is not 5 actionable because it is forward-looking. MTD at 16-17. 6 The PSLRA safe harbor precludes liability for forward-looking statements in either of two 7 circumstances: (1) “if they were identified as forward-looking statements and accompanied by 8 meaningful cautionary language,” or (2) “if the investors fail to prove the projections were made 9 with actual knowledge that they were materially false or misleading.” In re Cutera Sec. Litig., 610 10 F.3d 1103, 1111-12 (9th Cir. 2010); see 15 U.S.C. § 78u-5(c)(1). A forward-looking statement is 11 “any statement regarding (1) financial projections, (2) plans and objectives of management for 12 future operations, (3) future economic performance, or (4) the assumptions ‘underlying or related 13 to’ any of these issues.” No. 84 Emp.-Teamster Joint Council Pension Tr. Fund v. Am. W. 14 Holding Corp., 320 F.3d 920, 936 (9th Cir. 2003) (citing 15 U.S.C. § 78u-5(i)). 15 Statement 11 is located in the Form 10-K filed with the SEC dated March 16, 2020. See 16 SAC App. 1; Fernandes Decl., Ex. 16. The Form 10-K identifies the statement as forward- 17 looking. Fernandes Decl., Ex. 16 at 3. The statement provides that AcelRx may change its 18 commercialization plan. Any such change would necessarily be in the future. The statement falls 19 under the category of “plans and objectives of management for future operations.” Further, the 20 statement is accompanied by meaningful cautionary language. See id. Therefore, this statement is 21 protected by the PSLRA safe harbor. Plaintiffs have not alleged that Statement 11 is actionable. 22 Corporate Optimism 23 Statement 14 is that the DSUVIA launch was “progressing well with [the] healthcare 24 providers.” See SAC App. 1; SAC ¶ 150. Defendants argue that the statement is puffery, see 25 MTD at 17, and the Court agrees. “In the Ninth Circuit, ‘vague, generalized assertions of 26 corporate optimism or statements of mere puffing are not actionable material misrepresentations 27 under federal securities laws’ because no reasonable investor would rely on such statements.” In 1 Fusion-io, Inc. Sec. Litig., No. 13-CV-05368-LHK, 2015 WL 661869, at *14 (N.D. Cal. Feb. 12, 2 2015)). “Statements like ‘[w]e are very pleased with the learning from our pilot launch,’ ‘so far 3 we're getting really great feedback,’ and ‘we are very pleased with our progress to date,’ are 4 inactionable puffery.” Id. (quoting Wozniak v. Align Tech., Inc., 850 F. Supp. 2d 1029, 1036 5 (N.D. Cal. 2012)). Similarly, “statements projecting ‘excellent results,’ a ‘blowout winner’ 6 product, ‘significant sales gains,’ and ‘10% to 30% growth rate over the next several years’” were 7 held to be puffery, and therefore not actionable. In re Fusion-io, 2015 WL 661869, at *14 (citing 8 In re Cornerstone Propane Partners, L.P. Sec. Litig., 355 F. Supp. 2d 1069, 1087 (N.D. Cal. 9 2005)). The statement here—that the launch is “progressing well”—is similarly nonactionable 10 puffery. Further, as Defendants note, Plaintiffs do not allege that the launch was not “progressing 11 well.” See MTD at 17. This statement is not actionable. 12 Conclusion 13 The Court concludes that Plaintiffs have not pled falsity as to Statements 4-27, but it is a 14 close call as to Statements 1-3. The Court therefore turns to whether Plaintiffs have alleged 15 scienter. 16 2. Scienter 17 Scienter is a “mental state embracing intent to deceive, manipulate, or defraud.” Ernst & 18 Ernst v. Hochfelder, 425 U.S. 185, 193 n.12 (1976). To plead scienter, the complaint must “state 19 with particularity facts giving rise to a strong inference that the defendant acted with the required 20 state of mind.” 15 U.S.C. § 78u-4(b)(2)(A). Scienter is adequately pled when “all of the facts 21 alleged, taken collectively, give rise to a strong inference of scienter.” Tellabs, 551 U.S. 323. 22 This means that “[a] complaint will survive ... only if a reasonable person would deem the 23 inference of scienter cogent and at least as compelling as any opposing inference one could draw 24 from the facts alleged.” Id. at 324. The facts alleged “must not only be particular, but also must 25 ‘strongly imply [the defendant’s] contemporaneous knowledge that the statement was false when 26 made.’” In re Infonet Servs. Corp. Sec. Litig., 310 F. Supp. 2d 1080, 1102 (C.D. Cal. 2003) 27 (quoting In re Read-Rite, 335 F.3d 843, 847 (9th Cir. 2003)) (alteration in original). “Where, as 1 require that the Plaintiffs allege scienter with respect to each of the individual 2 defendants.” Oregon Pub. Emps. Ret. Fund v. Apollo Grp. Inc., 774 F.3d 598, 607 (9th Cir. 3 2014). 4 In their opposition to the motion to dismiss, Plaintiffs assert that scienter can be inferred 5 when holistically considering the following: (1) access to information and (2) core operations. 6 Opp. at 18-24. The Court finds that these bases do not give rise to a strong inference of scienter. 7 a. Access to Information 8 First, Plaintiffs assert that Defendants’ access to information undermining their public 9 statements supports scienter. Opp. at 18-23. Plaintiffs first point to the fact that Defendants had 10 multiple interactions with the FDA regarding DSUVIA, specifically the REMS, and these 11 negotiations put Defendants on notice that AcelRx would be subject to FDA scrutiny if it failed to 12 adhere to the REMS and that REMS compliance was its responsibility. Opp. at 18-19. But 13 Defendants’ awareness of FDA regulations and their work with the FDA in developing the REMS 14 do not strongly imply that they knew any specific statement identified above was false at the time 15 it was made. Further, Plaintiffs have not alleged that Defendants failed to comply with the REMS. 16 See SAC. Plaintiffs also assert that AcelRx submitted its tabletop display for DSUVIA to OPDP 17 prior to Defendant Angotti’s March 16, 2020 statement. Opp. at 19. But the fact that the tabletop 18 display was submitted to OPDP again does not indicate that Defendant Angotti knew that any 19 statement identified above was untrue. The fact that Defendants were aware that the FDA was 20 regulating its marketing does not give rise to an inference that Defendants would be aware that any 21 particular marketing material was misleading or otherwise not in compliance with the FDCA. 22 Plaintiffs also rely on the statements of seven former employees (“FEs”). Opp. at 19-23; 23 see SAC ¶¶ 71-113. The Court will first summarize the accounts of FEs 4-7, who were added for 24 the first time in the SAC, and it will then summarize the accounts of FEs 1-3. 25 The SAC alleges that FE4 was the Senior Director of Marketing, reported directly to 26 Angotti, and personally created the Tongue and Done campaign. SAC ¶¶ 90-92. FE4 said Angotti 27 was aware of the Tongue and Done slogan and that Defendant Palmer and other senior officers 1 the Tongue and Done slogan at certain identified medical conferences. Id. ¶¶ 94–99. 2 FE5 was the first sales representative the Company hired to promote DSUVIA. SAC ¶ 3 100. He confirmed that FE4 developed the Tongue and Done campaign and that Palmer and 4 Angotti weighed in on marketing materials. Id. ¶¶ 100–02. FE5 stated that Angotti attended 5 conferences in which the Company touted the Tongue and Done campaign to medical 6 professionals. Id. ¶¶ 103–04. 7 FE6 was a federal account director for the Company from July 2019 to November 2021. 8 SAC ¶ 105. He stated that the Company’s promotional review committee (“PRC”) approved 9 marking messages. Id. ¶ 106. As the SAC alleges, the medical department, run by Palmer, served 10 on this committee. Id. ¶¶ 33, 77, 106. FE6 explained that he had to inform healthcare 11 professionals that due to the Warning Letter, the Company would no longer be using the Tongue 12 and Done slogan. Id. ¶ 107. FE6 said the Warning Letter harmed the Company’s reputation. Id. ¶ 13 107. 14 FE7 was a regional medical director at the Company. SAC ¶ 108. He stated that he 15 expressed concerns about the Tongue and Done slogan to Angotti, Palmer, and his supervisor, 16 Gail Spahn. Id. ¶ 109. Specifically, FE7 raised concerns that the Tongue and Done campaign 17 oversimplified the use of a powerful opioid and contained sexual overtones that could be 18 misinterpreted. Id. He raised these concerns at a meeting with senior management, including 19 Angotti and Palmer, but Palmer told him that Tongue and Done was a marketing decision and thus 20 the medical affairs team should not get involved. Id. ¶ 110. FE7 stated that at the meeting, 21 Angotti responded to FE7’s concerns by saying that he trusted his marketing team. Id. Three 22 months later, FE7 again expressed his concerns to Spahn, and Spahn fired him shortly thereafter 23 on the basis that he was not supporting leadership’s decisions and she did not feel confident in him 24 supporting an opioid product. Id. ¶¶ 111-12. FE7 said that the Tongue and Done materials were 25 used at meetings, national sales meetings, medical affairs meetings, and strategic development 26 meetings. Id. ¶ 113. FE7 also recalled that Angotti attended a pain management conference 27 where AcelRx marketed DSUVIA using the “Tongue and Done” table drape and sales handouts. 1 FE1 worked as a contract marketing manager for AcelRx from June 2017 through March 2 2020 and as a marketing specialist from January 2016 through June 2017, and he reported to the 3 senior director of marketing. SAC ¶¶ 71-72. He stated that DSUVIA’s brand identity required 4 regular sign-off from AcelRx’s regulatory and compliance staff, and he confirmed FE6’s account 5 that the Company’s promotional review committee (“PRC”) approved marking messages to ensure 6 that content was FDA-compliant and that the PRC was in direct communication with the FDA. Id. 7 ¶¶ 76-78. 8 FE2 was a contract HR Consultant from June 2019 through August 2021. SAC ¶ 81. He 9 stated that Angotti provided final approval and would have reviewed and signed off on marketing 10 materials. Id. ¶ 85. 11 FE3 was a medical editor for Publicis Groupe (“Publicis”) from March 2018 to September 12 2018. SAC ¶ 86. Publicis’ Health division worked with AcelRx on the marketing materials for 13 DSUVIA, with the Senior Director of Marketing (FE4) as the primary contact. Id. ¶¶ 86-87. He 14 confirmed that DSUVIA was marketed to health care professionals in ambulatory surgical centers 15 and hospitals. Id. ¶ 88. 16 Defendants argue that these allegations are insufficient to support scienter. MTD at 19-21. 17 They argue that the allegations show nothing more than that certain individual Defendants were 18 aware of the promotional materials, not that Defendants intended to deceive investors. Id. at 20. 19 The Court agrees. The fact that Defendants Angotti and Palmer were aware of the 20 promotional materials and their use at conferences is not enough to raise a strong inference that 21 they intended to deceive investors or to engage in the Misbranding Violations through the use of 22 those materials. Further, the fact that the FE7 expressed concern about the Tongue and Done 23 slogan to Defendants Palmer and Angotti is not sufficient to raise an inference that they intended 24 to deceive investors. Cf. In re Rigel Pharms., Inc. Sec. Litig., 697 F.3d 869, 883 (9th Cir. 2012) 25 (stating that allegations that a defendant was aware of a fact was not sufficient to show the 26 defendant believed they made false or misleading statements about that fact). The FE allegations 27 do not give rise to a strong inference that the Defendants had a “mental state embracing intent to b. Core Operations 1 Plaintiffs also argue that the core operations theory supports scienter. Opp. at 23. Under 2 the core operations theory, “scienter may be imputed based on the inference that key officers have 3 knowledge of the core operations of the company.” Mulligan v. Impax Lab’ys, Inc., 36 F. Supp. 4 3d 942, 969 (N.D. Cal. 2014) (internal quotation marks and citation omitted). If a plaintiff 5 provides “‘allegations regarding a management’s role in the company’ that are ‘particular and 6 suggest that the defendant had actual access to the disputed information,’ and where ‘the nature of 7 the relevant fact is of such prominence that it would be absurd to suggest that management was 8 without knowledge of the matter,’” then falsity itself can support scienter. Zucco Partners, LLC v. 9 Digimarc Corp., 552 F.3d 981, 1000 (9th Cir. 2009) (quoting S. Ferry LP, No. 2 v. Killinger, 542 10 F.3d 776, 786 (9th Cir. 2008)). Plaintiffs argue that the core operations theory applies here 11 because AcelRx is a small company with minimal marketing staff, DSUVIA was the only 12 approved product, and the FE statements establish that the individual Defendants were involved 13 with the marketing campaign for DSUVIA. Opp. at 23. 14 Allegations that a company is small or that it has only one product are not sufficient to 15 raise a strong inference of scienter. See In re NVIDIA Corp. Sec. Litig., 768 F.3d 1046, 1064 (9th 16 Cir. 2014) (allegations of “flagship product” insufficient); Glazer Cap. Mgmt., LP v. Magistri, 549 17 F.3d 736, 747 (9th Cir. 2008) (holding “the mere size and nature of [the] business are not 18 sufficient to create a strong inference of scienter”). This case is not one of the “rare 19 circumstances” when scienter is adequately alleged through the core operations theory. See 20 Mulligan, 36 F. Supp. 3d at 969. 21 c. Other Warning Letters 22 While not discussed in the Scienter portion of their opposition brief, see Opp. at 18-24, 23 Plaintiffs do add to the SAC allegations about two other FDA warning letters, sent in 2008 and 24 2009, over drugs that were also subject to REMS, see SAC ¶¶ 43. To the extent that Plaintiffs 25 allege that these letters support scienter, the Court disagrees. The fact that the FDA sent warning 26 letters to other companies adds nothing to the scienter analysis. Defendants were clearly aware 27 that the marketing materials were subject to FDA regulation, as indicated by the fact that they 1 submitted the marketing materials to the FDA for review. The existence of these letters does not 2 give rise to an inference of scienter. 3 d. Holistic Review 4 After having determined that none of Plaintiffs' allegations, standing alone, is sufficient to 5 create a strong inference of scienter, the Court now considers the allegations holistically. See 6 Zucco, 552 F.3d at 992. Plaintiffs also argue that the totality of the allegations are sufficient to 7 support scienter. Opp. at 23-24. The Court finds that taken together, the facts do not evince such 8 fraudulent intent or deliberate recklessness as to make the inference of scienter cogent. Tellabs, 9 551 U.S. at 323. 10 3. Conclusion 11 The Court GRANTS the motion to dismiss the Rule 10b-5(b) claim WITH LEAVE TO 12 AMEND. 13 B. Claim 2: Section 10(b) and Rule 10b-5(a) and (c) 14 Plaintiffs also bring a claim under subsections (a) and (c) of Rule 10b-5, quoted above. 15 SAC ¶¶ 207-16. Defendants move to dismiss this claim. MTD at 22-25. 16 “To state a scheme liability claim, a plaintiff must show: ‘(1) that the defendant committed 17 a deceptive or manipulative act, (2) in furtherance of the alleged scheme to defraud, (3) with 18 scienter, and (4) reliance.’” Plumber & Steamfitters Loc. 773 Pension Fund v. Danske Bank A/S, 19 11 F.4th 90, 105 (2d Cir. 2021) (quoting In re Mindbody, Inc. Sec. Litig., 489 F. Supp. 3d 188, 216 20 (S.D.N.Y. 2020)). “And, of course, the deceptive or fraudulent scheme or activity must have 21 occurred ‘in connection with the purchase or sale of a[ ] security.’” Id. (alteration in original) 22 (quoting 17 C.F.R. § 240.10b-5). 23 Plaintiffs explain that the claim is based on an alleged “scheme to illegally market 24 DSUVIA beyond its permitted label through misleading advertisements to doctors who would 25 prescribe and oversee the administration of the drug to ‘enhance sales of DSUVIA.’” Opp. at 24 26 (quoting SAC ¶ 208). Plaintiffs argue that “[o]n the basis of that falsified marketing scheme, 27 Defendants ‘deceive[d] investors into believing the prospects and addressable market for DSUVIA 1 The claim fails. Plaintiffs argue that Defendants were reassuring investors that they were 2 in compliance with REMS and were marketing according to law while they were instead 3 promoting DSUVIA with the “Tongue and Done” slogan. Opp. at 24-25. Again, Plaintiffs have 4 not alleged a failure to comply with REMS. See SAC. And for the same reasons that Plaintiffs 5 have not alleged scienter as to the Misbranding Violations, they have also not alleged scienter as 6 to a scheme to defraud investors. There are no allegations that the Defendants had an intent to 7 engage in a scheme to defraud investors about the market size of DSUVIA. The Court already 8 determined there was no scienter as to the Misbranding Violations. And as Defendants point out, 9 Plaintiffs do not allege any inflated sales figures or enhanced market size. See Reply at 14-15. 10 This situation is distinguishable from the cases that Plaintiffs cite. See Opp. at 24. 11 Plaintiffs point to Klein v. Altria Group, Inc., in which the court determined that the plaintiffs had 12 adequately pled scheme liability where they alleged “that Defendants acted in concert to deceive 13 the FDA into not regulating mint [tobacco products] so that they could continue to target youth 14 with the mint product, including submitting falsified data and studies.” 525 F. Supp. 3d 638, 665 15 (E.D. Va. 2021). Further, Plaintiffs alleged “that [defendant] JUUL embarked on a years-long 16 effort to increase youth addiction and [defendant] Altria knew about this effort. Still, rather than 17 apprising investors of the risks associated with the effort, Defendants continued to publicly deny 18 JUUL's intention of targeting youths in an effort to avoid further litigation or regulation that could 19 curb their values.” Id. Defendants here did not submit falsified data or studies to the FDA to 20 avoid regulation. Instead, Defendants complied with FDA regulations, submitting its 21 advertisements to the FDA for approval. 22 Plaintiffs also point to Mart v. Tactile Systems Technology, Inc., which centered on the sale 23 of one of the defendant’s devices—the Flexitouch—for at-home treatment of certain diseases. 595 24 F. Supp. 3d 788, 799 (D. Minn. 2022). The court explained that “[i]n furtherance of the scheme, 25 Defendants allegedly exaggerated and distorted clinical study results and claims data analyses to 26 convey that Flexitouch's market size was three to four times greater than it actually was, and paid 27 illegal kickbacks to induce doctors and hospital staff to prescribe the Flexitouch.” Id. at 823 1 “allegedly issued false and misleading statements in furtherance of the scheme which was 2 intended to, and did, drive Flexitouch sales, and with it, [the defendant’s] revenues and share 3 price.” Id. (internal quotation marks and citation omitted). Defendants in this case did not 4 exaggerate any study results or data analyses. Further, there are no allegations as to either the 5 actual market size, or what Plaintiffs claim was an inflated market size. 6 Finally, Plaintiffs cite to West Virginia Pipe Trades Health & Welfare Fund v. Medtronic, 7 Inc., 57 F. Supp. 3d 950 (D. Minn. 2014). In that case, the plaintiffs alleged that the defendants 8 engaged in a scheme to deceive investors and artificially inflate the stock price. Id. at 964-65. 9 The plaintiffs alleged that the defendant’s clinical studies revealed safety risks with its product, so 10 the defendant engaged in a scheme to conceal these safety risks. Id. at 965. The defendant did so 11 by “forg[ing] relationships, including financial relationships, with physician authors who 12 published research articles in respected medical journals and knowingly concealed in those 13 original articles, or omitted altogether, known facts regarding [the product’s] adverse side effects 14 observed in clinical trials,” and these articles “overstated apparent disadvantages of alternate . . 15 . procedures . . . as opposed to treatment with [the product].” Id. The defendant paid the 16 physician authors, and the defendant’s employees edited the articles to remove information that 17 could have informed the public and doctors about the harmful side effects of the product. Id. No 18 such behavior was present here. 19 The Court determines that Plaintiff has not alleged a scheme liability claim. The Court 20 GRANTS the motion to dismiss the Rule 10b-5(a) and (c) claim WITHOUT LEAVE TO 21 AMEND. 22 C. Claim 3: Section 20(a) 23 Plaintiffs bring a claim against Defendants Angotti, Asadorian, and Palmer for violation of 24 Section 20(a) of the Exchange Act. SAC ¶¶ 217-23. Defendants move to dismiss this claim. 25 MTD at 25 n.5. 26 Section 20(a) of the Exchange Act extends liability for § 10(b) violations to those who are 27 “controlling persons” of the alleged violations. Hollinger v. Titan Cap. Corp., 914 F.2d 1564, 1 Plaintiffs must first allege a violation of § 10(b). Lipton v. Pathogenesis Corp., 284 F.3d 1027, 2 1035 n.15 (9th Cir. 2002). They have failed to do so here. 3 The Court GRANTS the motion to dismiss the § 20(a) claim against Defendants Angotti, 4 Asadorian, and Palmer WITH LEAVE TO AMEND. 5 V. ORDER 6 The Court GRANTS Defendants’ motion to dismiss the SAC WITH LEAVE TO AMEND 7 all claims except Claim 2. Although the Court is granting leave to amend all of the falsity 8 allegations, it seems unlikely that Plaintiffs will do better on the risk factors, earnings call 9 statement, sales and marketing efforts, SOX certifications and controls, or forward-looking 10 statements. However, Plaintiffs requested one further opportunity to allege sufficient facts, which 11 is allowed. Amendment of allegations related to scienter is allowed. Scheme liability, alleged in 12 || Claim 2, is dismissed WITHOUT LEAVE TO AMEND. Plaintiffs have never provided any 5 13 plausible factual allegations to support that claim. Plaintiffs SHALL file a third amended 14 || complaint (“TAC”), if they are able to rectify the defects discussed above, no later than sixty days 3 15 from the date of this Order. No parties or claims may be added without leave of Court. Plaintiffs a 16 SHALL provide a chart with the TAC including a numbered list of the false and misleading 3 17 statements, and for each statement: (1) a citation to the pleading; (2) the identity of the speaker; (3) 18 the date of the statement; (4) the location of the statement; (5) evidence the statement was false 19 || when made; and (6) evidence of scienter with respect to that statement. Plaintiffs SHALL provide 20 a redline of the TAC against the SAC. 21 IT IS SO ORDERED. 22 23 Dated: July 7, 2023 BETH LABSON FREEMAN 25 United States District Judge 26 27 28